NCT02609828

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Oct 28, 2015
Primary completion: Sep 29, 2019
Completion date: Jul 21, 2020
First posted: —
Last posted: —
Enrollment: 255
Arms / groups: 2 / —
Source: AACT · pre-existing

Sponsors

PfizerLead sponsor
L'Hospitalet de LlobregatOverall official - principal investigator
Albert Einstein Israelite HospitalOverall official - principal investigator
Sungkyunkwan UniversityOverall official - principal investigator
Yonsei UniversityOverall official - principal investigator
Instituto do Cancer do Estado de São PauloOverall official - principal investigator
Hospital Universitario Fundación AlcorcónOverall official - principal investigator
Hospital de Cancer de Barretos - Fundacao Pio XIIOverall official - principal investigator
Complexo Hospitalario Universitario de A CoruñaOverall official - principal investigator
Oncology department of Nemocnice BenesovOverall official - principal investigator
Nemocnice HoroviceOverall official - principal investigator
Masarykuv onkologicky ustav, Klinika komplexni onkologicke peceOverall official - principal investigator
Slovak Research CenterOverall official - principal investigator
Hospital Sanitas La MoralejaOverall official - principal investigator
Ballarat Health ServicesOverall official - principal investigator
Ambulancia Klinickej onkologie FNsP Nove ZamkyOverall official - principal investigator
Nuhr Medical CenterOverall official - principal investigator
Polyclinique de L'ormeauOverall official - principal investigator
Poradnia Medycyny Paliatywnej Hospicjum PaliumOverall official - principal investigator
Powiatowy Zespo Zakadow Opieki Zdrowotnej w Bdzinie, Oddzia Opieki Paliatywnej Szpital CzeladOverall official - principal investigator
Niepliczny Zakad Opieki Zdrowotnej Zespo Medyczno-Opieku-Czy Alicja KlucznaOverall official - principal investigator
Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC w GdanskuOverall official - principal investigator
Hetenyi G KorhazOverall official - principal investigator
Oncocenter Onclogie Clinica S.R.LOverall official - principal investigator
Wilhelminenspital der Stadt WienOverall official - principal investigator
Instituto de Oncologia de RosarioOverall official - principal investigator
Fundacion Favaloro Para La Docencia e Investigacion MedicaOverall official - principal investigator
Departmental Hosptital of VendeeOverall official - principal investigator
Nishinomiya Municipal Central HospitalOverall official - principal investigator
Klinikum KlagenfurtOverall official - principal investigator
Sanera, s.r.o.Overall official - principal investigator
Stowarzyszenie Przyjacio Chorych HospicjumOverall official - principal investigator
Sue Ryder HomeOverall official - principal investigator
The National Cancer CenterOverall official - principal investigator
Monash UniversityOverall official - principal investigator
Bajcsy-Zsilinszky HospitalOverall official - principal investigator
Keimyung UniversityOverall official - principal investigator
Seoul National UniversityOverall official - principal investigator
BiovirtusOverall official - principal investigator
Oncolab SRLOverall official - principal investigator
Universidad Autonoma de MadridOverall official - principal investigator
PfizerStudy director
University of EdinburghOverall official - principal investigator
Eli LillyCollaborator
Fundacao Antonio PrudenteOverall official - principal investigator
National Institutes of Health (NIH)Overall official - principal investigator
Faculdade de Medicina do ABCOverall official - principal investigator
Flinders UniversityOverall official - principal investigator
Hallym UniversityOverall official - principal investigator
University AlicanteOverall official - principal investigator
Velindre NHS TrustOverall official - principal investigator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.